Adult Brain Tumors
Conditions
Keywords
adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor
Brief summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma multiforme or gliosarcoma.
Detailed description
OBJECTIVES: Primary * Determine the objective response rate in patients with recurrent epidermal growth factor receptor (EGFR)-positive and PTEN wild-type glioblastoma multiforme or gliosarcoma treated with erlotinib hydrochloride. Secondary * Assess the response rate in patients who also EGFRVIII mutant and PTEN wild type glioblastoma multiforme or gliosarcoma. * Determine the progression-free survival of patients treated with this drug. OUTLINE: This is an open-label study. Patients are stratified according to concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no). Patients receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may receive additional erlotinib hydrochloride after 1 year at their physician's discretion. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Interventions
DRUGerlotinib hydrochloride
Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
Sponsors
National Cancer Institute (NCI)
Genentech, Inc.
Michael Prados
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of glioblastoma multiforme (GBM) or gliosarcoma (GS) * In first, second, or third relapse * History of low-grade glioma with transformation to GBM or GS allowed * Considered to be in first relapse at first documented diagnosis of GBM or GS * Measurable or evaluable disease by contrast MRI * Must have failed prior treatment that included external beam radiotherapy with or without chemotherapy * Epidermal growth Factor Receptor-positive and PTEN wild-type by immunohistochemistry PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% * WBC ≥ 3,000/mm³ * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 10 g/dL (transfusion allowed) * SGOT \< 2 times upper limit of normal (ULN) * Bilirubin \< 2 times ULN * Creatinine \< 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective hormonal or barrier method contraception before, during, and for at least 12 weeks after completion of study treatment * No other cancer within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix * No active infection * No other disease that would obscure toxicity or dangerously alter study drug metabolism PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 4 weeks since prior and no concurrent radiotherapy * At least 4 weeks since prior and no concurrent cytotoxic chemotherapy agents (e.g., temozolomide) (6 weeks for nitrosoureas) * At least 2 weeks since prior and no concurrent noncytotoxic chemotherapy agents * At least 4 weeks since prior investigational agents * No other concurrent investigational agents * No prior erlotinib hydrochloride or other epidermal growth factor receptor tyrosine-kinase inhibitors * At least 2 weeks since prior enzyme-inducing antiepileptic drugs (EIAEDs), if not used concurrently with study treatment * Concurrent continuous use of EIAEDs allowed provided the patient has received the drug for ≥ 2 weeks prior to study treatment * No concurrent immunotherapy or anticancer hormonal therapy * No other concurrent antineoplastic or antitumor agents
Exclusion criteria
Patients meeting any of the following criteria are ineligible for study entry: * Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years are ineligible. * Patients must not have active infection * Patients must not be pregnant/breast feeding and must agree to practice adequate contraception. Women of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to treatment. Patients must not be pregnant because of the uncertainty that study drug may be potentially embryotoxic. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation, and continue approximately 12 weeks after the study is completed. If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Prior treatment with Tarceva, or other EGFR tyrosine-kinase inhibitors will not be allowed. * Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease Response Measured Objectively by MRI of Brain | Every 8 weeks or as indicated | Lack of disease progression indicates response to treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Progress-free Survival (PFS) | Until first observation of progressive disease, non-reversible neurologic progression or permanently increased steroid requirement (stable disease only), death due to any cause (up to 16 weeks) | Patients with stable or responding disease will continue treatment until tumor progression is determined |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 erlotinib hydrochloride (Tarceva) self-administered in an open-label, unblinded manner to all patients enrolled in the study. | 6 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants |
| Age Continuous | 44 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 6 participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 6 |
| serious Total, serious adverse events | 6 / 6 |
Outcome results
Primary
Disease Response Measured Objectively by MRI of Brain
Lack of disease progression indicates response to treatment
Time frame: Every 8 weeks or as indicated
Population: 5 participants evaluable while receiving study treatment
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Disease Response Measured Objectively by MRI of Brain | Disease progression prior to 8 weeks | 4 participants |
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Disease Response Measured Objectively by MRI of Brain | Disease responsive at 8 Weeks | 1 participants |
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Disease Response Measured Objectively by MRI of Brain | Disease responsive at 16 Weeks | 0 participants |
Secondary
Duration of Progress-free Survival (PFS)
Patients with stable or responding disease will continue treatment until tumor progression is determined
Time frame: Until first observation of progressive disease, non-reversible neurologic progression or permanently increased steroid requirement (stable disease only), death due to any cause (up to 16 weeks)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Duration of Progress-free Survival (PFS) | 2 weeks PFS | 1 participants |
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Duration of Progress-free Survival (PFS) | 3 weeks PFS | 1 participants |
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Duration of Progress-free Survival (PFS) | 6 weeks PFS | 2 participants |
| Oral Erlotinib Hydrochloride (Tarceva) Daily on Days 1-28 | Duration of Progress-free Survival (PFS) | 12 weeks PFS | 1 participants |